KR-20260064992-A - Composition For Preventing Loss Or Regenerating Peripheral Nerve cell Comprising LHRH

Abstract

The present invention relates to a pharmaceutical composition or quasi-drug composition for the prevention or treatment of peripheral nervous system diseases comprising LHRH (Luteinizing Hormone-Releasing Hormone) as an active ingredient, a food composition for the prevention or regeneration of peripheral nerve damage, a health functional food, a feed composition, a feed additive composition, and a cosmetic composition, and a method for the prevention or treatment of peripheral nervous system diseases comprising the step of administering to an individual a composition comprising LHRH, a fragment thereof, or an analog thereof as an active ingredient. Since the LHRH of the present invention has efficacy in preventing and regenerating peripheral nerve damage, it can be usefully utilized as a composition for the prevention, treatment, and improvement of peripheral nervous system diseases in general.

Inventors

• 황선욱
• 김민석
• 하이옌 장

Assignees

• 고려대학교 산학협력단

Dates

Publication Date

20260508

Application Date

20241030

Claims (18)

1. A pharmaceutical composition for the prevention or treatment of peripheral nervous system diseases comprising LHRH (Luteinizing Hormone-Releasing Hormone), a fragment thereof, or an analog thereof as an active ingredient.
2. In paragraph 1, The above LHRH is a pharmaceutical composition consisting of the amino acid sequence of SEQ ID NO. 1.
3. In paragraph 1, A pharmaceutical composition in which the above peripheral nervous system disease is a pain-associated disease or a sensory abnormality disease.
4. In paragraph 3, A pharmaceutical composition wherein the above-mentioned pain-associated disease is one or more selected from the group consisting of neuropathic pain, inflammatory pain, osteoarthritis pain, postoperative pain, cancer pain, pain associated with metastatic cancer, pain caused by cancer treatment chemotherapy agents, trigeminal neuralgia, burning pain, acute herpes and post-herpetic neuralgia, occipital neuralgia, sympathetic dystrophy, fibromyalgia, gouty pain, burn pain, phantom limb pain, complex regional pain syndrome, idiopathic pain syndrome, migraine, and chronic pain of unknown etiology.
5. In paragraph 3, A pharmaceutical composition wherein the above-mentioned sensory abnormality is one or more selected from the group consisting of anesthesia, proprioceptive abnormality, hyposensitivity or hypersensitivity, paralytic loss of sensation, tingling, itching, itching accompanied by inflammation, histaminergic itching, nonhistaminergic itching, itching of unknown cause, itching accompanied by dryness, atopic dermatitis, psoriasis, urticaria, contact dermatitis, nodular pruritus, scabies, insect bites, athlete's foot, and lichen planus.
6. A food composition for preventing or regenerating peripheral nerve damage comprising LHRH (Luteinizing Hormone-Releasing Hormone), a fragment thereof, or an analog thereof as an active ingredient.
7. In paragraph 6, The above LHRH is a food composition consisting of the amino acid sequence of SEQ ID NO. 1.
8. A health functional food for the prevention or regeneration of peripheral nerve damage containing LHRH (Luteinizing Hormone-Releasing Hormone), a fragment thereof, or an analog thereof as an active ingredient.
9. In paragraph 8, The above LHRH is a health functional food composed of the amino acid sequence of SEQ ID NO. 1.
10. A quasi-drug composition for the prevention or improvement of peripheral nervous system diseases, comprising LHRH (Luteinizing Hormone-Releasing Hormone), a fragment thereof, or an analog thereof as an active ingredient.
11. In Paragraph 10, The above LHRH is a quasi-drug composition consisting of the amino acid sequence of SEQ ID NO. 1.
12. A feed composition for preventing or regenerating peripheral nerve damage comprising LHRH (Luteinizing Hormone-Releasing Hormone), a fragment thereof, or an analog thereof as an active ingredient.
13. In Paragraph 12, The above LHRH is a feed composition consisting of the amino acid sequence of SEQ ID NO. 1.
14. A cosmetic composition for preventing or regenerating peripheral nerve damage comprising LHRH (Luteinizing Hormone-Releasing Hormone), a fragment thereof, or an analog thereof as an active ingredient.
15. In Paragraph 14, The above LHRH is a cosmetic composition consisting of the amino acid sequence of SEQ ID NO. 1.
16. A method for the prevention or treatment of peripheral nervous system diseases comprising the step of administering a composition containing LHRH (Luteinizing Hormone-Releasing Hormone), a fragment thereof, or an analog thereof as an active ingredient to an individual other than a human.
17. In Paragraph 16, The above LHRH is a method for prevention or treatment consisting of the amino acid sequence of SEQ ID NO. 1.
18. In Paragraph 16, A method of prevention or treatment in which the above composition is administered orally, rectally, transdermally, intravenously, intramuscularly, intraperitoneally, intramedullaryly, intrathecally, intradermally, or subcutaneously to an individual other than a human.

Description

Composition for Preventing or Regenerating Peripheral Nerve Damage Containing LHRH as an Active Ingredient The present invention relates to a pharmaceutical composition, quasi-drug composition, food composition, health functional food, feed composition, feed additive composition, and cosmetic composition for the prevention or treatment of peripheral nervous system diseases comprising LHRH (Luteinizing Hormone-Releasing Hormone) as an active ingredient, and a method for the prevention or treatment of peripheral nervous system diseases comprising the step of administering to an individual a composition comprising LHRH, a fragment thereof, or an analog thereof as an active ingredient. Research on the regeneration of damaged nerves has been actively conducted for a long time. In clinical practice, surgical methods for treating traumatic peripheral nerve injuries primarily consist of complex procedures designed to create an optimal environment for nerve regeneration after removing damaged tissue at the site of injury. This process is generally carried out by directly connecting or fusing the nerve endings. While awaiting spontaneous nerve regeneration, outpatient treatments are also implemented using electrical stimulation to maintain muscle contraction and inhibit the degeneration of muscle-nerve junctions. Additionally, extra surgical methods such as peripheral nerve grafting are performed; combined with long-term physical therapy, this prevents muscle weakness and atrophy and promotes nerve sprouting. Mechanical orthopedic devices have also been utilized to protect joints and preserve muscles and ligaments surrounding the injured area. Meanwhile, various experimental techniques for nerve regeneration are being implemented, including methods that connect nerves using biocompatible tubes and methods that combine drug therapy to reduce nerve damage and promote regeneration. Currently, drugs used for the treatment and regeneration of peripheral nerves are known to have insufficient efficacy or side effects, necessitating the emergence of new technologies. Accordingly, the inventors intend to provide a composition for preventing peripheral nerve loss and promoting regeneration, as well as a method for preventing and treating peripheral nerve damage using the same. Figure 1 shows the results of confirming the nerve fiber recovery effect in a sciatic nerve compression injury model according to LHRH treatment. Figure 2 shows the results of confirming the effect of nerve function recovery in a sciatic nerve compression injury model according to LHRH treatment. The present invention will be explained in more detail below through the following examples. However, these examples are intended to illustrate the invention and the scope of the invention is not limited to these examples. Example 1. Confirmation of nerve fiber recovery by LHRH in a sciatic nerve compression injury model The nerve fiber recovery effect of Luteinizing hormone-releasing hormone (LHRH) (Sequence No. 1) was analyzed by measuring the length of nerve fibers using a sciatic nerve crush model mouse, which is a type of standardized nerve injury model. Specifically, the thighs of anesthetized mice were incised to externally expose the sciatic nerve, and nerve damage was induced by compressing the sciatic nerve for 15 seconds using micro-forceps. Eight days after inducing nerve damage, LHRH consisting of the amino acid sequence of SEQ ID No. 1 was prepared (Anigen) and injected into the spinal canal at a dose of 5.91 mg/kg. One week later, to check the degree of nerve fiber recovery, the sciatic nerve bundle was excised and stained with the nerve fiber marker NF200 (Fig. 1a). The stained tissue was photographed using a fluorescence microscope, and the fluorescence intensity appearing in the images of the stained peripheral nerve fibers was measured to determine the length of the peripheral nerve fibers recovered after injury using FIJI software. Fluorescence signal intensity is shown in Fig. 1b, and a graph comparing the AUC of each group is shown in Fig. 1c. The sham group exposed the sciatic nerve but omitted the step of compressing the sciatic nerve, while the control group (vehicle) was treated with an excipient. The statistical significance of the experimental data was tested using one-way ANOVA or two-way ANOVA. *P<0.05 indicates a significant difference from the excipient-treated control group at the same time point. As a result, as shown in Figure 1, significant nerve bundle recovery was confirmed in the sciatic nerve of mice injected with LHRH compared to the control group (vehicle) administered with the excipient. Example 2. Confirmation of nerve function recovery by LHRH in a sciatic nerve compression injury model The regeneration of peripheral nerve function by LHRH (Sequence No. 1) for peripheral nerve injury was evaluated using a peripheral sciatic nerve crush model mouse, which is a type of standardized nerve injury model. Specifically, the